MedTrace Logo

HMPL004-6599 Phase I Dose-escalating Study

NCT03597971 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-12-17

No results posted yet for this study

Summary

To assess the safety and tolerability of single and multiple doses of HMPL004-6599 in healthy male volunteers

Conditions

Interventions

DRUG

HMPL004-6599

For each cohort, 6 subjects will receive HMPL004-6599

DRUG

Placebo

For each cohort, 2 subjects will receive placebo

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    collaborator INDUSTRY

  • Société des Produits Nestlé (SPN)

    collaborator INDUSTRY

  • Nutrition Science Partners Limited

    lead INDUSTRY

Principal Investigators

  • Wu Yan, MD · Hutchison Medipharma Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-20
Primary Completion
2018-11-19
Completion
2018-11-19

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03597971 on ClinicalTrials.gov